54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
Abiogenesis Clinpharm Private Limited is an emerging contract research organization (CRO) that provides client specific services in clinical development of drugs and devices. Our research wing helps clients in clinical development program of drugs and devices at every step. Our expertise comes from an experienced team of professionals having credentials of successfully conducting national and international clinical trials across all phases of clinical development. Abiogenesis Clinpharm Private Limited is capable of delivering quality work from early proof of concept to late phase development including post launch product lifecycle management.
We are a team of highly skilled people having expertise in the area of clinical research and work experience in leading clinical development programs of many reputed organizations. Our team epitomise scientific knowledge and operational excellence in clinical research industry. We have the ability to integrate the primary concept of clinical development into project management plan with micro level execution strategies. We have direct operating experience from initial planning to project execution from Phase I to Phase IV studies in different therapeutic areas across the globe. Our expertise should be utilised in following services.
Absorption Systems, a Pharmaron company, is a full-service nonclinical CRO developing innovative services and solutions for the pharmaceutical, biotech, medical device and regenerative medicine industry. Our services include research and testing for small molecules, large molecules, biologics, medical device and cell and gene therapy products. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated outcomes when they occur. The company's facilities are strategically located in Philadelphia, San Diego, and Boston, servicing hundreds of customers throughout the world. Our focus is to maintain accuracy, timelines, and reliability at every stage of development. For more information on the company's comprehensive contract services and applied research programs, please visit absorption.com.
Accelsiors is a scientifically-driven, global, full-service Contract Research Organization (CRO). We support the Pharma industry globally to accelerate and manage every activity across clinical drug development.
Since 2002, we have been committed to providing Sponsors working in highly complex disease indications with the scientific knowledge, regulatory expertise and quality operations necessary to achieve their development objectives.
Accelsiors expertise includes studies in the following areas:
Accutest, a global independent and internationally accredited Contract Research Organisation (“CRO”), with more than 20 years of experience and over 700+ employees in supporting the end-to-end services for global bio-pharmaceutical, biotech, medical device, nutraceutical and FMCG companies. Accutest is the market leader among independent CROs, with the highest quality standards and quick turnaround times. We have a strong regulatory track record and numerous accreditation/approvals from global regulatory agencies.
We offer services in 3 verticals:
1. Bio-availability and Bio-equivalence studies (BA/BE) -
2. Clinical Development Services (CDS)- Phase II - IV studies, Post marketing, Investigator initiated & stand alone services (medical writing, regulatory consultancy, clinical data management)
3. Biologics Services - Solutions for biosimilars, novel biologics and non-biological complex generics
Successfully cleared below inspections:
USFDA – 33 times (latest Nov, 2018)
WHO – 23 times (latest Jan, 2019)
DCGI- 20 times (latest Oct, 2016)
EMA – 8 times (latest Dec, 2017)